Affiner les résultats

Cytokines and inflammatory mediators : 25. Certolizumab Pegol has a Different Profile from the other Anti-TNFS, Including Golimumab, in a Variety of in Vitro Assays

Nesbitt, Andrew ; Fossati, Gianluca ; Whittall, Catherine E. ; Askari, Ayman ; Middleton, Jim ; Astorri, Elisa ; Bombardi, Michele ; Peakman, Mark ; Pozzilli, Paolo ; Pitzalis, Costantino ; Goodall, Jane C. ; Ellis, Lou ; McNeill, Louise ; Gaston, Hill J. ; Mittal, Gayatri A. ; Mageed, Rizgar A. ; Chernajovsky, Yuti ; Hawkins, P. N. ; Kuemmerle-Deschner, J. B. ; Hachulla, E. ; Cartwright, R. ; Kone-Paut, I. ; Hoyer, J. ; Quartier, P. ; Smith, J. ; Gattorno, M. ; Leslie, K. ; Gul, A. ; Widmer, A. ; Patel, N. ; Preiss, R. ; Lachmann, H. J. ; Krausgruber, Thomas ; Blazek, Katrina ; Smallie, Timothy ; Lockstone, Helen ; Sahgal, Natasha ; Alzabin, Saba ; Hussell, Tracy ; Feldmann, Marc ; Udalova, Irina ; Jeffery, Louisa E. ; Raza, Karim ; Filer, Andrew ; Sansom, David M.

In: Rheumatology, 2011, vol. 50, p. iii52-iii55